Learning Objective 1:Recognize the role of adjuvant systemic therapy for resected lung cancer.

Learning Objective 2:Understand some of the unique toxicities of the small molecule tyrosine kinase inhibitors in use for lung cancer treatment.

Learning Objective 3:Appreciate the role of immune checkpoint inhibitors in lung cancer management

Session date: 
03/21/2017 - 6:45am to 7:45am CDT
UCMC E-500
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Dr. Phillip Hoffman, MD